Aims/hypothesis Diabetic peripheral neuropathy (DPN) is a chronic microvascular complication that is strongly associated with poor glycaemic control and also with a worse prognosis. We aimed to evaluate the predictors of the development and progression of DPN in a cohort of high-risk patients with type 2 diabetes. Methods In a prospective study, 477 patients with type 2 diabetes were clinically assessed for the presence of DPN at baseline and after a median follow-up of 6.2 years (range 2-10 years). Clinical laboratory data were obtained at study entry and throughout the follow-up. Aortic stiffness was assessed by the carotid-femoral pulse wave velocity (cf-PWV) at baseline. Multivariate Poisson regression analysis was used to examine independent predictors of the development/progression of DPN. Results At baseline, 135 patients (28%) had DPN, and during follow-up 97 patients (20%) had either a new development or a worsening of DPN. Patients who showed a development or progression of DPN were taller and had a longer duration of diabetes, a greater prevalence of other microvascular complications and hypertension, greater aortic stiffness and poorer glycaemic control than patients who did not have new or progressive neuropathy. After adjustments for the baseline prevalence of DPN, the patient's age and sex, and the time interval between DPN assessments; an increased aortic stiffness (cf-PWV >10 m/s) were predictive of new/progressive DPN (incidence rate ratio 2.04, 95% CI 1.28, 3.23; p=0.002).
Introduction
Typical diabetic peripheral neuropathy (DPN) is defined as a 'symmetrical, length-dependent sensorimotor polyneuropathy attributable to metabolic and microvessel alterations as a result of chronic hyperglycaemia exposure and cardiovascular risk covariates' [1] and affects both large and small nerve fibres. Its pathogenesis involves interactions between vascular and metabolic factors [2] . Indeed, microcirculatory alterations similar to those observed in diabetic retinopathy and nephropathy are associated with pathological alterations in the nerves [3] . Most importantly, DPN is an important cause of disability, is associated with a higher mortality and reduced quality of life [1, 4, 5] and imposes a tremendous cost on healthcare systems [5, 6] .
Long-tem hyperglycaemia seems to be the most important risk factor for DPN; currently, besides improving glycaemic control, there is no other effective treatment to prevent the development or progression of DPN. However, neuropathy can develop despite intensive glucose control, suggesting that other risk factors are involved in the pathophysiology of DPN. Although intensive glucose control has been shown to prevent neuropathy in type 1 diabetes [7, 8] , similar control seems to be less effective in type 2 diabetes [9] [10] [11] [12] . These studies suggest that factors other than chronic hyperglycaemia, including metabolic factors such as dyslipidaemia, chronic inflammation and vascular risk factors, are probably interacting in the development of DPN [2, [7] [8] [9] [10] [11] [12] . Thus, identifying other possibly modifiable factors for the development and progression of DPN could have potential future implications for treatment.
Central (aortic) arterial stiffness has been proposed as a measure of the burden of cumulative vascular risk factors [13] . Patients with type 2 diabetes show increased aortic stiffness [14] , and associations between the presence of DPN and increased arterial stiffness have previously been demonstrated [15, 16] . Nonetheless, longitudinal relationships between increased aortic stiffness and the development/progression of DPN have not yet been investigated. Hence, we aimed to explore the independent predictors of the development/ progression of DPN in a cohort of high-risk patients with type 2 diabetes, paying particular attention to the prognostic importance of increased aortic stiffness, assessed by its gold standard method, the carotid-femoral pulse wave velocity (cf-PWV) [17] .
Methods
This was a prospective study, nested within the Rio de Janeiro Type 2 Diabetes Cohort Study, that involved 477 patients with type 2 diabetes who were enrolled between 2004 and 2008 and re-evaluated for the diagnosis of peripheral neuropathy between 2013 and 2014 in the diabetes outpatient clinic of our tertiary-care University Hospital. All participants gave written informed consent, and the local Ethics Committee had previously approved the study protocol.
The characteristics of this cohort, the baseline procedures and the diagnostic definitions have been detailed elsewhere [15, [18] [19] [20] . In brief, the inclusion criteria were all adults with type 2 diabetes who were aged up to 80 years and had either any microvascular (retinopathy, nephropathy or neuropathy) or macrovascular (coronary, cerebrovascular or peripheral artery disease) complication, or at least two other modifiable cardiovascular risk factors. The exclusion criteria were morbid obesity (BMI ≥40 kg/m 2 ), advanced renal failure (serum creatinine >180 μmol/l or an estimated GFR [eGFR] <30 ml/ min/1.73 m 2 ) or the presence of any serious concomitant disease limiting life expectancy. All the patients were submitted to a standard baseline protocol that included a thorough clinical examination, including a complete evaluation for peripheral neuropathy and a history of alcohol intake, a laboratory evaluation and an assessment of aortic stiffness in terms of cf-PWV measurement.
The diagnostic criteria for chronic complications of diabetes have previously been detailed [15, [18] [19] [20] . Briefly, CHD was diagnosed by clinical electrocardiographic criteria or by positive ischaemic stress tests. Cerebrovascular disease was diagnosed by a history and physical examination, and peripheral arterial disease by an ankle-brachial index <0.9. Diabetic retinopathy was evaluated by an ophthalmologist. The diagnosis of nephropathy (incipient or overt) needed at least two findings of albuminuria ≥30 mg/24 h or a confirmed reduction in eGFR (<60 ml/min/1.73 m 2 ; or serum creatinine >130 μmol/l). Clinic BP was measured three times using a digital oscillometric BP monitor (HEM-907XL; Omron Healthcare, Kyoto, Japan) with a suitably sized cuff on two occasions 2 weeks apart at study entry. The first measurement at each visit was discarded, and the BP considered was the mean of the last two readings from each visit. Arterial hypertension was diagnosed if the mean systolic BP (SBP) was ≥130 mmHg or the mean diastolic BP (DBP) was ≥80 mmHg, or if antihypertensive drugs had been prescribed.
Laboratory evaluation included fasting glycaemia, HbA 1c , serum creatinine, lipids and vitamin B 12 . Those patients (3.4%) with low serum vitamin B 12 levels (<150 pmol/l) were started on monthly intramuscular vitamin B 12 administration. Albuminuria and proteinuria were evaluated in two nonconsecutive sterile 24 h urine collections. Aortic stiffness was evaluated by cf-PWV, using the foot-to-foot velocity method with Complior equipment and software (Artech Medical, Paris, France), as previously described [14, 17] . The direct carotid-femoral distance was corrected by a factor of 0.8, and a cf-PWV >10 m/s was considered to represent increased aortic stiffness, as recommended [21] . Patients with aortoiliac occlusive disease were excluded because of its known attenuating effect on PWV measurements. The patients were followed up regularly at least three or four times a year until December 2014. All patients had at least two to four annual HbA 1c and clinic BP measurements.
Assessment of peripheral neuropathy Neuropathic symptoms were evaluated by a standard validated questionnaire [22] , which allocates between 0 and 9 points to specific symptoms. Patients were asked about pain or discomfort in their legs: if the patient described burning, numbness or tingling, a score of 2 was assigned; fatigue, cramping or aching scored 1. The presence of symptoms in the feet was assigned a score of 2, in the calves a score of 1 and elsewhere a score of 0. The exacerbation of symptoms only at night scored 2 vs 1 for both day and night and 0 for daytime only. A score of 1 was given if the symptoms had ever woken the patient. The patients were asked if any manoeuvre could reduce their symptoms: walking was assigned a score of 2, standing was 1 and sitting or lying down was 0 [22] . Patients were classified as having no specific symptoms (0-2 points) or mild (3-4), moderate (5) (6) or severe (7-9 points) symptoms.
The clinical signs of peripheral neuropathy were assessed by the Neuropathy Disability Score (NDS) [22] and by sensation in the feet tested with a Semmes-Weinstein 10 g/5.07 monofilament. The NDS combines examination of the ankle reflex with testing for vibration (with 128 Hz tuning fork), pinprick and temperature (with a cold tuning fork) sensations on both big toes, and gives a total score ranging from 0 (no signs) to 10 points. The sensory evaluations score either 0 (present) or 1 (reduced/absent), whereas the ankle reflex scores 0 (normal), 1 (present with reinforcement) or 2 (absent) [22] . Patients were classified as having mild neuropathic signs (3-5 points), moderate signs (6) (7) (8) or severe signs (9-10). In addition, sensation over the feet was tested with the Semmes-Weinstein monofilament on four plantar sites for each foot (the big toe and first, third and fifth metatarsal heads); if at least two insensitive regions were found, this was considered abnormal. All the examinations were repeated twice by the same independent observer, and in cases of disagreement a third examination was performed. The minimum criteria for the diagnosis of peripheral neuropathy were the presence of moderate symptoms (regardless of the presence of signs) or the presence of mild symptoms with moderate neuropathic signs. Hence, mild symptoms with or without mild signs were not considered adequate for establishing a diagnosis of peripheral neuropathy.
Patients were evaluated for neuropathy at study entry and after a median time interval of 6.2 years. In those with peripheral neuropathy at baseline, the criteria for defining the progression of the neuropathy were as follows: an increase in the neuropathic symptom score from mild to moderate or from moderate to severe; an increase in the NDS from mild or moderate to severe; a doubling in the number of insensitive areas on monofilament examination (for those with at least two insensitive areas at the first assessment); and the occurrence of classic non-traumatic diabetic foot ulceration or toe amputation.
Statistical analysis Continuous data were described as means (SD) or as medians (interquartile range). The primary endpoint was the new development of established peripheral neuropathy or the progression of a pre-existent neuropathy, according to the criteria detailed above. Patients with and without a development/progression of peripheral neuropathy were compared by unpaired t test (for continuous normal variables), Mann-Whitney test (for continuous asymmetrical variables) and χ 2 test (for categorical variables). Independent associations between aortic stiffness (analysed as both continuous and categorical cf-PWV) and the development/ progression of DPN were evaluated by multivariate Poisson (loglinear) regression analyses with increasing levels of statistical adjustment. In addition, the independent predictors of the occurrence of the primary endpoint were examined by multivariate Poisson regression.
Candidate variables to enter the multivariate regression models were the following: age, sex, BMI, height, duration of diabetes, smoking status, physical activity, dyslipidaemia, arterial hypertension, diabetic treatment (metformin and insulin), antihypertensive treatment (number and classes of drugs), mean first-year SBP, each macrovascular (coronary and cerebrovascular disease) and each microvascular (retinopathy, nephropathy and neuropathy) diabetic complication at baseline, HbA 1c level and increased aortic stiffness. Regardless of their significance, age, sex, the presence of peripheral neuropathy at baseline and the time interval between DPN assessments were forced into all the models. A forward selection procedure was used to select the independent predictors with a p value <0.10 as the criterion to enter and remain in the models. HbA 1c measurements at baseline and as mean levels at the first and second years of follow-up were evaluated in separate models adjusted for the same covariates as the original predictive model. Separate analyses were also performed for development of new DPN (i.e. including only patients without DPN at baseline) and progression of DPN (i.e. including only patients with DPN at baseline).
The Poisson regression results were presented as incidence rate ratios (IRR), calculated as the exponential of the estimated regression coefficients [23] , with their respective 95% CIs, and a two-tailed p value <0.05 was considered significant. Statistics were performed using SPSS version 19.0 (SPSS Inc, Chicago, IL, USA).
Results
At baseline, 135 patients (28%) had DPN. After a median time interval of 6 years (interquartile range 5-7 years, total range 2-10 years,), 97 patients (20%) showed either newly developed (50 patients) or worsened (47 patients) DPN. Of the 47 patients with progressive DPN, 17 developed non-traumatic foot ulcers (classic diabetic foot) or had toe/forefoot amputations, 12 at least doubled the number of insensitive points on monofilament examination, and 18 changed their neuropathy symptom score from mild to moderate or from moderate to Table 1 outlines the characteristics of all the patients and of those with and without a development/progression of DPN. Patients who had newly developed or progressive peripheral neuropathy were taller and had a longer duration of diabetes, a greater prevalence of other microvascular complications and greater aortic stiffness than patients who did not show a development or progression of neuropathy. They also had a greater prevalence of hypertension and higher SBP at baseline and during follow-up, although they used more antihypertensive medications. In addition, these patients showed poorer glycaemic control at baseline and during follow-up, although they used insulin more frequently than those without a development/progression of DPN. There were no differences in the proportion of patients who were currently drinkers of alcohol, or in serum vitamin B 12 levels, between those with and without a development/progression of DPN. Table 2 presents the results of the independent associations between aortic stiffness and the development/progression of DPN from Poisson regression with several increasing adjustments. Both continuous and categorical cf-PWV predicted the development/progression of DPN in all models. An increased aortic stiffness (>10 m/s) at baseline doubled the incidence rate of developing/worsening DPN, whereas each 1 m/s increment in cf-PWV increased by 11% the incidence rate of the development/progression of DPN during follow-up in the most adjusted models. Table 3 shows the other independent predictors of the development/progression of DPN. These were the presence of nephropathy, arterial hypertension (but not clinic SBP levels), height and poor glycaemic control during the first year of follow-up. Similar results were seen after entering the albuminuria status (<30 vs ≥30 mg/24 h) and eGFR separately instead of the diagnosis of diabetic nephropathy: the presence of microalbuminuria was associated with an 80% increased Candidate variables to enter the model were: age, sex, BMI, height, duration of diabetes, smoking status, alcohol intake, physical activity, dyslipidaemia, arterial hypertension, diabetic treatment (metformin and insulin), antihypertensive treatment (number and classes of drugs), mean first-year SBP, each macrovascular (coronary and cerebrovascular disease) and microvascular (retinopathy, nephropathy and neuropathy) diabetic complication at baseline, mean first-year HbA 1c and increased aortic stiffness. Regardless of their significance, age, sex, the presence of peripheral neuropathy at baseline and the time interval between DPN assessments were forced into the model risk of the development/progression of DPN (IRR 1.79, 95% CI 1.14, 2.86; p=0.012), whereas the eGFR was not associated with the development/progression of DPN ( p=0.29).The presence of diabetic retinopathy at baseline was not associated with a development/worsening of DPN regardless of entering or not entering nephropathy into the multivariate models. In terms of glycaemic control, only the mean HbA 1c during the first year of follow-up, but not the baseline HbA 1c or its mean level for the second year, predicted the development/ progression of peripheral neuropathy. In separate analyses (Table 4) , increased aortic stiffness and the presence of nephropathy were predictors of both the development and the progression of DPN (albeit being of borderline significance for the progression of DPN). However, the 95% CIs of the IRRs for height, mean HbA 1c and arterial hypertension were too wide to allow a meaningful interpretation of these results because of the lower statistical power of these separate analyses.
Discussion
This prospective study over a 6.2 year median follow-up has three main findings. First, it confirms the role of good glycaemic control in preventing the development/ progression of DPN for high-risk, mostly elderly patients with long-standing type 2 diabetes. Second, it demonstrates for the first time the importance of increased aortic stiffness as a predictor of the future development/progression of DPN. Finally, it shows the contribution of other covariates such as vascular risk factors (hypertension), anthropometric factors (height) and the presence of other microvascular complications (nephropathy or abnormal albuminuria) to helping in the identification of individuals at high risk of the development/ progression of DPN. These findings have potential clinical implications: beyond achieving optimal glycaemic control, the control of blood pressure, reduction in albuminuria and attenuation of aortic stiffness may contribute to preventing DPN. This speculation, however, clearly needs to be addressed in future prospective interventional trials.
The association of increased aortic stiffness at baseline with the future development/progression of DPN is a new finding. We [15] and others [16, 24] have previously reported that aortic stiffness was associated with DPN in cross-sectional analyses, but none of these had evaluated longitudinal temporal relationships. Although observational cohort studies did not allow causal inferences, this finding suggests a common physiopathological link between macrovascular and microvascular abnormalities in type 2 diabetes. Increased aortic stiffness may simply be a surrogate measure of the cumulative burden of vascular risk factors on the vessel wall over time, as previously proposed [13, 25] , reflecting the well-accepted interaction between metabolic and vascular factors in the pathogenesis of DPN [1, 2] . Increased aortic stiffness can directly damage the microcirculation, including the vasa nervorum, by increasing the transmission of wider, harmful pulsatile pressure waves as a result of the loss of the normal aortic buffering function [13, 14] . Alternatively, both DPN and aortic stiffness may share common determinants, such as oxidative stress, endothelial dysfunction, the formation of advanced glycation end-products and vessel wall inflammation. Interestingly, we recently reported [26] that unstiffening of the aorta can be achieved in patients with type 2 diabetes by optimal glycaemic and blood pressure control, which were also associated with the prevention of DPN.
Although the cornerstone role of optimal glycaemic control in preventing the development/progression of DPN in patients with type 1 diabetes is undisputed [1, 7, 8, 27] , its importance in type 2 diabetes is more debatable. In addition, even for patients with type 1 diabetes, current strategies for optimising glycaemic control are insufficient to fully prevent or delay the development of DPN seen on long-term follow-up [28] . The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial [9] , although it reported a lack of benefit of intensive glucose control for the primary microvascular endpoints (a composite of advanced renal, retinal and neuropathy endpoints), did find a benefit in terms of preventing most Our results corroborate these previous studies by showing that, after a longer median follow-up of 6.2 years, the mean HbA 1c level during the first year of follow-up was shown to be a predictor of the future development/progression of DPN. This observation has an important clinical message: good glycaemic control should be established as soon as possible, ideally during the first year of follow-up, in order to prevent the development/progression of DPN.
The other independent predictors of the development/ progression of DPN have been reported in previous epidemiological studies involving patients with type 1 or type 2 diabetes [8, 27, 31, 32] ; this is particularly true of the presence of arterial hypertension [8, 27] , a modifiable vascular risk factor. It is possible that the treatment of hypertension, as well as of other cardiovascular risk factors, could interfere with the development of peripheral arterial disease [34] , an important contributor to classic diabetic foot ulceration.
There are, however, potential limitations to the interpretation of this study's results. First, the time interval between the baseline and final DPN evaluation of the participants was variable, ranging from 2 up to 10 years. However, there were no differences in the follow-up time between the patients with and without a development/progression of DPN (median 73 vs 75 months, respectively), and the multivariate regression analyses were further adjusted for the time interval between the two DPN assessments.
Second, this study began in 2004, so we used for the diagnosis of DPN the most commonly employed criterion, which was a minimum of two abnormalities in symptoms and signs, that is, clinically evident DPN, which corresponds to probable diabetic sensorimotor polyneuropathy in the more recent definition [1] . The current standard definition of DPN remains challenging as it combines clinical and electrophysiological criteria [1] . Nonetheless, other longitudinal studies investigating the development/progression of diabetic neuropathy have also not performed nerve conduction examinations for diagnosis [8-11, 30, 32, 33] .
Third, assessing clinical DPN involves measures that are prone to a varying extent of subjectivity or observer bias. However, these measurement inaccuracies would actually underestimate the statistical significance towards the null hypothesis for the associations between risk factors and the development/progression of DPN. Finally, this study enrolled middle-aged to elderly high-risk individuals with longstanding type 2 diabetes. Therefore, our findings may not be generalisable to younger patients with recent-onset diabetes. Furthermore, this was an observational cohort so neither cause-and-effect relationships nor physiopathological mechanisms can be inferred, but only speculated.
In conclusion, this study demonstrated that increased aortic stiffness at baseline predicted the future development or progression of DPN, independent of metabolic control, suggesting a physiopathological link between macrovascular and microvascular abnormalities in type 2 diabetes. Prospective future studies with intensive multifactorial management, including the optimal control of metabolic and cardiovascular risk factors, possibly accompanied by a reduction in aortic stiffness, should address whether these interventions would be able to prevent or delay the development of DPN in patients with type 2 diabetes.
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